2014 ASCO AM Public - Monday - ASCO


Powered by SmugMug Log In
309

309

Chicago, IL - The 2014 ASCO Annual Meeting - "Maurice Perol, MDat Abstract #LBA8006^: ""REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy,"" Lung Cancer (Non-small Cell Metastatic) Oral Abstract Session Keyword: AM14_Maurice_Perol" at the American Society of Clinical Oncology Annual Meeting here today, Monday June 2, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Scott Morgan 2014 Technical Questions: todd@medmeetingimages.com

14ASCO4295aAM14_Maurice_Perol ASCO 2014